

Exploring motivators, barriers, and access to genetic testing for a rare eye disease

Mallorie T. Tam^{1,2,3}, Alonso Daboub^{1,2,3}, Hayami Lou^{1,2,3}, Tanya L., Feng^{1,2,3}, Katarzyna Kabacińska^{1,2,3}, Julie M. Robillard^{1,2,3}

¹University of British Columbia, Department of Medicine, Division of Neurology, Vancouver, British Columbia, Canada

²BC Children's and Women's Hospital, Vancouver, British Columbia, Canada

³Neuroethics Canada, University of British Columbia, Vancouver, BC, Canada

BACKGROUND

Aniridia is a congenital eye condition characterized by a complete or partial absence of the iris.

It occurs in **1 in 50,000 to 100,000** births worldwide.

Most aniridia cases originate from a **pathogenic variation in the PAX6 gene**, affecting development of eye structures.

Genetic testing plays a significant role in the diagnosis and treatment of aniridia.

There are **ethical considerations** around the use of genetic information to support individuals with aniridia.



It is an ethical imperative to improve access to accurate and current information about genetic testing and counselling to better support individuals with aniridia.

METHODS



Conducted a targeted search and analysis of **N=108 Canadian policies and public-facing information** about access and reimbursement for genetic testing for aniridia.



Conducted and analyzed **N=8 semi-structured interviews** with individuals living with aniridia.

RESULTS

Table 1. Summary of Canadian policy and public-facing search on access to genetic testing

Lack of clear information on where to get genetic testing for rare diseases	No mentions of genetic testing for rare diseases on federal and provincial government websites
Limited details on reimbursement for genetic testing	Only 4 of the top 10 insurance companies in Canada cover diagnostic services

Table 2. Examples of reasons for genetic testing, and perceived barriers and benefits

Reasons for Genetic Testing	<ul style="list-style-type: none"> Family planning Learn about other health conditions associated with pathogenic variation Learn about treatment options
Perceived Barriers to Genetic Testing	<ul style="list-style-type: none"> Lack of information about genetic testing Cost of testing Logistical errors during testing
Perceived Benefits of Genetic Testing	<ul style="list-style-type: none"> Learn about specific pathogenic variation and treatment options Help future generations and contribute to research

OBJECTIVES

To examine:

- 1) Canadian public-facing information** about access to services and reimbursement policies for genetic testing for rare diseases;
- 2) Motivators and barriers for genetic testing** for individuals living with aniridia;
- 3) Benefits and risks of genetic testing** for rare neurological conditions.

MOVING FOWARD

- Access to genetic counselling** should be a priority to support informed decision-making around testing
- Following neuroethics principles, the implications of **opportunities to enroll in research and clinical trials** that offer genetic testing should be discussed to protect participants' well-being and rights
- Future work in this area should capture perspectives from a **diverse sample**

ACKNOWLEDGEMENTS

We would like to thank **Dr. Elizabeth Simpson** for her expertise and support, and the **Canadian Institutes of Health Research** for funding this project.

Read our papers!

